• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Influence of aggregate size on the binding and activation of the first component of human complement by soluble IgG aggregates.聚集体大小对可溶性IgG聚集体与人补体第一成分的结合及激活的影响。
Immunology. 1982 Apr;45(4):705-13.
2
Possible mechanisms of the first step of the classical complement activation pathway: binding and activation of C1.经典补体激活途径第一步的可能机制:C1的结合与激活。
Immunology. 1978 Dec;35(6):873-84.
3
C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.C1 灭活剂:其作为可溶性 IgG 聚集体对经典补体途径激活的调节因子的效能。
Immunology. 1983 Jun;49(2):215-22.
4
Activation of C1 by soluble IgG aggregates as detected by a novel one-step hemolytic assay that specifically measures the proenzyme form of C1s.通过一种新型一步溶血试验检测可溶性IgG聚集体对C1的激活,该试验专门测量C1s的酶原形式。
J Immunol. 1983 Oct;131(4):1924-9.
5
Reduction of the complement activation capacity of soluble IgG aggregates and immune complexes by IgM-rheumatoid factor.IgM类风湿因子降低可溶性IgG聚集体和免疫复合物的补体激活能力。
Immunology. 1985 Jul;55(3):555-64.
6
Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.新生C3b和C4b对C1激活的控制:一种反馈抑制机制。
J Immunol. 1986 May 1;136(9):3378-83.
7
The effect of specific antibody on antibody-independent interactions between E. coli J5 and human complement.特异性抗体对大肠杆菌J5与人补体之间非抗体依赖性相互作用的影响。
J Immunol. 1982 Feb;128(2):707-11.
8
The relationship between the binding ability and the rate of activation of the complement component C1.补体成分C1的结合能力与激活速率之间的关系。
Immunology. 1980 Sep;41(1):179-85.
9
Demonstration of the interaction of native C1 with monomeric immunoglobulins and C1 inhibitor.天然C1与单体免疫球蛋白及C1抑制剂相互作用的演示
J Immunol. 1985 Apr;134(4):2559-63.
10
Kinetic measurement of the interaction of rheumatoid factor with IgG-coated latex particles and the influence of the first component of human complement.类风湿因子与IgG包被乳胶颗粒相互作用的动力学测量以及人补体第一成分的影响。
Clin Exp Immunol. 1980 Jan;39(1):154-63.

引用本文的文献

1
Unveiling the impact of TolC efflux protein on host tissue adherence, complement evasion, and diagnostic potential.揭示 TolC 外排蛋白对宿主组织黏附、补体逃避和诊断潜力的影响。
Infect Immun. 2024 Nov 12;92(11):e0041924. doi: 10.1128/iai.00419-24. Epub 2024 Oct 11.
2
DNA Nanostructure-Templated Antibody Complexes Provide Insights into the Geometric Requirements of Human Complement Cascade Activation.DNA 纳米结构模板化抗体复合物为人补体级联激活的几何要求提供了见解。
J Am Chem Soc. 2024 May 15;146(19):13455-13466. doi: 10.1021/jacs.4c02772. Epub 2024 May 4.
3
IgG cooperativity - Is there allostery? Implications for antibody functions and therapeutic antibody development.IgG 协同性——存在别构效应吗?对抗体功能和治疗性抗体开发的影响。
MAbs. 2017 Nov/Dec;9(8):1231-1252. doi: 10.1080/19420862.2017.1367074. Epub 2017 Aug 16.
4
Effect of complement on sizes of model immune complexes.补体对模型免疫复合物大小的影响。
Dokl Biochem Biophys. 2014;458:167-9. doi: 10.1134/S1607672914050020. Epub 2014 Nov 4.
5
Effect of medium pH and antibody Fc fragment on the size of model immune complexes.培养基pH值和抗体Fc片段对模型免疫复合物大小的影响。
Dokl Biochem Biophys. 2013 Nov;453:286-7. doi: 10.1134/S1607672913060045. Epub 2014 Jan 3.
6
Determination of severity of murine IgA nephropathy by glomerular complement activation by aberrantly glycosylated IgA and immune complexes.通过异常糖基化 IgA 和免疫复合物引起的肾小球补体激活来确定小鼠 IgA 肾病的严重程度。
Am J Pathol. 2012 Oct;181(4):1338-47. doi: 10.1016/j.ajpath.2012.06.038. Epub 2012 Aug 5.
7
Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.抗体的强效人类免疫缺陷病毒中和活性和补体溶解活性并非必然相关。
J Virol. 2008 Apr;82(8):3834-42. doi: 10.1128/JVI.02569-07. Epub 2008 Jan 30.
8
C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.C1 灭活剂:其作为可溶性 IgG 聚集体对经典补体途径激活的调节因子的效能。
Immunology. 1983 Jun;49(2):215-22.
9
C1 inactivator-C1s complexes in inflammatory joint disease.炎症性关节疾病中的C1灭活剂-C1s复合物
Clin Exp Immunol. 1983 Sep;53(3):521-8.
10
Differential precipitation of the Clq subcomponent of the first complement component (C1) by polyethylene glycol from normal human serum and sera of patients with collagen diseases.用聚乙二醇从正常人血清和胶原疾病患者血清中对第一补体成分(C1)的Clq亚成分进行差异沉淀。
Clin Exp Immunol. 1984 Aug;57(2):495-501.

本文引用的文献

1
CHROMATOGRAPHIC SEPARATION OF THE FIRST COMPONENT OF COMPLEMENT AND ITS ASSAY ON A MOLECULAR BASIS.补体第一成分的色谱分离及其分子基础分析
J Immunol. 1963 Dec;91:851-8.
2
Chromatographic resolution of the first component of human complement into three activities.将人类补体的第一成分通过色谱法分离为三种活性。
J Exp Med. 1963 Jun 1;117(6):983-1008. doi: 10.1084/jem.117.6.983.
3
Isolation of a thermolabile serum protein which precipitates gamma-globulin aggregates and participates in immune hemolysis.一种热不稳定血清蛋白的分离,该蛋白可沉淀γ-球蛋白聚集体并参与免疫溶血。
Proc Soc Exp Biol Med. 1961 Feb;106:291-5. doi: 10.3181/00379727-106-26313.
4
The relationship between the binding ability and the rate of activation of the complement component C1.补体成分C1的结合能力与激活速率之间的关系。
Immunology. 1980 Sep;41(1):179-85.
5
The first component of complement. I. Purification and properties of native C1.补体的第一成分。I. 天然C1的纯化及特性
J Immunol. 1980 Jul;125(1):390-5.
6
Antigen-independent activation of the first component of complement C1 by chemically crosslinked rabbit IgG-oligomers.通过化学交联的兔IgG寡聚体对补体C1第一成分进行抗原非依赖性激活。
FEBS Lett. 1980 Apr 7;112(2):152-4. doi: 10.1016/0014-5793(80)80168-2.
7
Activation of the early components of the classical complement pathway under physiologic conditions.在生理条件下经典补体途径早期成分的激活。
J Immunol. 1981 May;126(5):1769-73.
8
Dimeric, trimeric and tetrameric complexes of immunoglobulin G fix complement.免疫球蛋白G的二聚体、三聚体和四聚体复合物可固定补体。
Biochem J. 1980 Jun 1;187(3):775-80. doi: 10.1042/bj1870775.
9
Titration of the first component of complement on a molecular basis: suitability of IgM and unsuitability of IgG hemolysins as sensitizer.补体第一成分的分子基础滴定:IgM作为致敏剂的适用性及IgG溶血素作为致敏剂的不适用性
Immunochemistry. 1969 May;6(3):461-7. doi: 10.1016/0019-2791(69)90302-4.
10
The requirement for the association of two adjacent rabbit gamma-G-antibody molecules in the fixation of complement by immune complexes.在免疫复合物固定补体过程中两个相邻兔γ-G抗体分子缔合的必要性。
J Immunol. 1968 Feb;100(2):407-13.

聚集体大小对可溶性IgG聚集体与人补体第一成分的结合及激活的影响。

Influence of aggregate size on the binding and activation of the first component of human complement by soluble IgG aggregates.

作者信息

Doekes G, Vanes L A, Daha M R

出版信息

Immunology. 1982 Apr;45(4):705-13.

PMID:7068172
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1555415/
Abstract

The interaction between small aggregates of human IgG and the first component of human complement was studied. Stabilized soluble IgG aggregates of restricted size were prepared by heat aggregation of human IgG, followed by sucrose-density ultracentrifugation. Human C1 was isolated in its precursor form by euglobulin precipitation, followed by gel filtration and immunoadsorption. A C1 preparation was obtained of which more than 90% was still in its unactivated form. Soluble aggregates containing 20, 10 or 5 molecules IgG, and monomeric IgG were tested for their ability to bind and to activate C1. The binding of C1 was determined by C1 consumption, whereas the activation of C1 was measured as the increased ability of the C1 preparation to consume purified human C4 after the incubation with the aggregates. The three aggregates tested and monomeric IgG were all able to bind and to activate C1, but the efficiency of both processes markedly increased with increasing aggregate-size. Furthermore, it was found that all four preparations activated an appreciable amount of C1 at concentrations that did not result in any detectable C1 fixation. These results confirm earlier suggestion that C1 can be activated during a short, transient binding to small aggregates or immune complexes that have a low avidity for C1, after which the activated form, C1, is released into the medium.

摘要

研究了人IgG小聚集体与人补体第一成分之间的相互作用。通过人IgG的热聚集,然后进行蔗糖密度超速离心,制备了大小受限的稳定可溶性IgG聚集体。通过优球蛋白沉淀,然后进行凝胶过滤和免疫吸附,以其前体形式分离出人C1。获得了一种C1制剂,其中90%以上仍处于未活化形式。测试了含有20、10或5个IgG分子的可溶性聚集体以及单体IgG结合和激活C1的能力。通过C1消耗来确定C1的结合,而C1的激活则通过在与聚集体孵育后C1制剂消耗纯化人C4的能力增加来衡量。测试的三种聚集体和单体IgG都能够结合并激活C1,但随着聚集体大小的增加,这两个过程的效率都显著提高。此外,发现所有四种制剂在不会导致任何可检测到的C1固定的浓度下都能激活相当数量的C1。这些结果证实了早期的推测,即C1在与对C1亲和力低的小聚集体或免疫复合物短暂结合期间可以被激活,之后活化形式的C1释放到培养基中。